Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
19 stopped studies mapped to Childhood Acute Myeloid Leukemia and descendants · 89% state a reason
Over the 19 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07498465 | A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After… | Phase 1 | withdrawn | Mar 27, 2026 | Children's Oncology Group | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT04678336 | CD123 Redirected T Cells for AML in Pediatric Subjects | Phase 1 | terminated | Dec 21, 2020 | University of Pennsylvania | Administrative reasons | Other (stated, no rule matched) |
| NCT03537599 | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute… | Phase 1 / Phase 2 | terminated | May 25, 2018 | Sumithira Vasu | Poor acccrual | Other (stated, no rule matched) |
| NCT05622591 | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive…(Pediatric AML) | Phase 1 | withdrawn | Nov 18, 2022 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem… | Phase 1 / Phase 2 | terminated | Oct 8, 2007 | City of Hope Medical Center | Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than… | Enrollment / accrual |
| NCT05077423 | A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute… | Phase 1 | terminated | Oct 14, 2021 | Y-mAbs Therapeutics | Study terminated due to business priorities | Sponsor / business decision |
| NCT00119366 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and… | Phase 2 | terminated | Jul 13, 2005 | Fred Hutchinson Cancer Center | Funding ended before target accrual was reached; participants are no longer being examined or… | Enrollment / accrual |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid… | Phase 1 / Phase 2 | terminated | Jul 13, 2012 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT01177540 | Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in… | Phase 2 | terminated | Aug 9, 2010 | Eisai Inc. | The study was terminated early due to enrollment difficulties and the futility of observing… | Efficacy / futility |
| NCT04326439 | AflacLL1901 (CHOA-AML) | Phase 2 | terminated | Mar 30, 2020 | Emory University | Due to unforeseen circumstances, the study team was limited in enrolling patients on this trial;… | Enrollment / accrual |
| NCT02587871 | Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute… | Phase 2 | withdrawn | Oct 27, 2015 | University of Southern California | PI decided not to pursue study | Other (stated, no rule matched) |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT01801046 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | Phase 1 | terminated | Feb 28, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT02791919 | Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children,… | Phase 1 | withdrawn | Jun 7, 2016 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or… | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01655875 | AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy…(BMTAMD3100) | Phase 1 | terminated | Aug 2, 2012 | Emory University | lack of patient enrollment | Enrollment / accrual |
| NCT00096148 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly… | Phase 2 | terminated | Nov 9, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00042796 | Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 5, 2026source: clinicaltrials